An individualised treatment algorithm for tumour stage 1 glottic squamous cell carcinoma

Aydil U., Akmansu M., Kizil Y., Yazici O., Ustun S., Karaloglu F., ...Daha Fazla

JOURNAL OF LARYNGOLOGY AND OTOLOGY, sa.11, ss.1127-1133, 2013 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1017/s0022215113002363
  • Dergi Adı: JOURNAL OF LARYNGOLOGY AND OTOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1127-1133
  • Anahtar Kelimeler: Laryngeal Cancer, Glottis, Radiotherapy, Laser Therapy, Laryngectomy, ANTERIOR COMMISSURE INVOLVEMENT, LASER MICRORESECTION, CO2-LASER SURGERY, LOCAL-CONTROL, RADIOTHERAPY, CANCER, T1A, FAILURE, PRESERVATION, CORDECTOMY
  • Gazi Üniversitesi Adresli: Evet

Özet

Objective: To report and discuss the outcome of a treatment algorithm for patients with tumour stage 1 glottic squamous cell carcinoma. Method: A retrospective outcome analysis study was performed using data from a tertiary referral centre. Results: Sixty-nine patients were treated with radiotherapy and 26 with surgery, in accordance with the treatment algorithm. Five-year overall survival rates were the same for both treatment groups (92 per cent). Five-year disease-specific survival rates were 100 per cent for surgery, 98 per cent for radiotherapy and 99 per cent overall. The overall 5-year laryngeal preservation rate was 89.1 per cent, being 95.7 per cent for surgery patients and 86.7 per cent for radiotherapy patients (p=0.502). There was no significant association between laryngeal preservation rates and age (p=0.779), anterior commissure involvement (p=0.081), tumour stage (1a or 1b) (p=0.266) or treatment modality (surgery or radiotherapy; p=0.220). There was no significant difference in local recurrence rates between the two treatment groups (19.3 per cent for radiotherapy vs 10.0 per cent for surgery; p=0.220). The overall 5-year regional recurrence rate was 1.2 per cent. Conclusion: Tumour stage 1 glottic carcinoma can be managed with different treatment modalities, following an individualised treatment algorithm, with results comparable to published outcomes.